Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible?

Table 1 First-line systemic therapy for advanced biliary tract cancers recommended by the National Comprehensive Cancer Network guidelines

Ref.	Regimen	Median OS (months)	Median PFS (months)	ORR (%)	DCR (%)	n
Valle et al[4] 2010	Gemcitabine + cisplatin	11.7	8.0	/	81.4	410
Sahai et al[14], 2018	Nab-paclitaxel + gemcitabine	12.4	7.7	30	66	74
André et al[15], 2008	Gemcitabine + oxaliplatin	8.8	3.4	14.9	50.7	67
Kim et al[16], 2019	Capecitabine + oxaliplatin	10.6	5.8	15.7	58.3	114
Knox et al[17], 2005	Gemcitabine + capecitabine	14.0	7.0	31	73	45
Oh et al[7], 2022	Durvalumab + gemcitabine + cisplatin	12.8	7.2	26.7	85.3	685
Kelley et al[3], 2023	Pembrolizumab + gemcitabine + cisplatin	12.7	6.5	29	75	1069

OS: Overall survival; PFS: Progression-free survival; ORR: Objective response rate; DCR: Disease control rate.

Table 2 Published results of nab-paclitaxel combination chemotherapy

Ref.	Regimen	Median OS (months)	Median PFS (months)	ORR (%)	DCR (%)	n
Shroff et al[8], 2019	Nab-paclitaxel + gemcitabine + cisplatin	19.2	11.8	45	84	60
Zhang et al[9], 2023	Nab-paclitaxel + S-1	13.2	6	27.5	70.6	54
Pressiani et al[10], 2024	Nab-paclitaxel + gemcitabine + oxaliplatin	12.4	6.3	20.89	67.15	67
Xu et al[5], 2024	Nab-paclitaxel + capecitabine	14.1	4.4	23.26	69.77	44

OS: Overall survival; PFS: Progression-free survival; ORR: Objective response rate; DCR: Disease control rate.